IMNM insider trading — Immunome Inc.
No open-market insider purchases or sales were filed for Immunome Inc. (IMNM) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent IMNM insider transactions
Every Form 4 filed by Immunome Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | M · Option exercise · 10b5-1 | Direct | 18,000 | $1.35 | $24K | Form 4 |
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | S · Sale · 10b5-1 | Direct | 13,200 | $25.32 | $334K | Form 4 |
| Sep 11, 2026 | Higgins Jack | Chief Scientific Officer | G · Gift · 10b5-1 | Direct | 8,800 | — | — | Form 4 |
| Aug 12, 2026 | Barchas Isaac | Director | S · Sale · 10b5-1 | Direct | 11,048 | $27.25 | $301K | Form 4 |
| Aug 11, 2026 | Barchas Isaac | Director | S · Sale · 10b5-1 | Indirect | 62,291 | $26.23 | $1.63M | Form 4 |
| Aug 10, 2026 | Barchas Isaac | Director | S · Sale · 10b5-1 | Indirect | 10,125 | $26.07 | $264K | Form 4 |
| Aug 7, 2026 | Barchas Isaac | Director | S · Sale · 10b5-1 | Indirect | 15,248 | $26.06 | $397K | Form 4 |
| Aug 6, 2026 | Barchas Isaac | Director | S · Sale · 10b5-1 | Indirect | 20,840 | $26.06 | $543K | Form 4 |
| Aug 4, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | M · Option exercise · 10b5-1 | Direct | 90,616 | $11.89 | $1.08M | Form 4 |
| Aug 4, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | S · Sale · 10b5-1 | Direct | 90,616 | $25.09 | $2.27M | Form 4 |
| Jul 23, 2026 | Siegall Clay B | President and CEO | A · Grant/award | Direct | 180,000 | — | — | Form 4 |
| Jul 23, 2026 | Higgins Jack | Chief Scientific Officer | A · Grant/award | Direct | 38,250 | — | — | Form 4 |
| Jul 23, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | A · Grant/award | Direct | 31,250 | — | — | Form 4 |
| Jul 23, 2026 | Stoneman Sandra G. | CHIEF LEGAL OFFICER & GC | A · Grant/award | Direct | 38,250 | — | — | Form 4 |
| Jul 23, 2026 | Rosett Max | Chief Financial Officer | A · Grant/award | Direct | 47,250 | — | — | Form 4 |
| Jul 23, 2026 | Tsai Philip | Chief Technical Officer | A · Grant/award | Direct | 38,250 | — | — | Form 4 |
| Jul 23, 2026 | Lechleider Robert | Chief Medical Officer | A · Grant/award | Direct | 54,000 | — | — | Form 4 |
IMNM insider trading FAQ
Are insiders buying IMNM stock?
Not on the open market. In the last 90 days, Immunome Inc. insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading IMNM?
No insider bought or sold on the open market in the last 90 days.
Where does IMNM insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.